ABSTRACT
Mycolactone, a lipid-like toxin, is the major virulence factor of Mycobacterium ulcerans, the etiological agent of Buruli ulcer. Its involvement in lesion development has been widely described in early stages of the disease, through its cytotoxic and immunosuppressive activities, but less is known about later stages. Here, we revisit the role of mycolactone in disease outcome and provide the first demonstration of the pro-inflammatory potential of this toxin. We found that the mycolactone-containing mycobacterial extracellular vesicles produced by M. ulcerans induced the production of IL-1ß, a potent pro-inflammatory cytokine, in a TLR2-dependent manner, targeting NLRP3/1 inflammasomes. We show our data to be relevant in a physiological context. The in vivo injection of these mycolactone-containing vesicles induced a strong local inflammatory response and tissue damage, which were prevented by corticosteroids. Finally, several soluble pro-inflammatory factors, including IL-1ß, were detected in infected tissues from mice and Buruli ulcer patients. Our results revisit Buruli ulcer pathophysiology by providing new insight, thus paving the way for the development of new therapeutic strategies taking the pro-inflammatory potential of mycolactone into account.
Subject(s)
Buruli Ulcer/immunology , Inflammation/immunology , Interleukin-1beta/immunology , Macrolides/immunology , Animals , Buruli Ulcer/metabolism , Buruli Ulcer/pathology , Extracellular Vesicles/metabolism , Humans , Inflammation/metabolism , Inflammation/microbiology , Interleukin-1beta/metabolism , Macrolides/metabolism , Macrolides/toxicity , Mice , Mice, Inbred C57BL , Mycobacterium ulceransABSTRACT
Clusterin (Clu), an extracellular chaperone, exhibits characteristics of soluble innate immunity receptors, as assessed by its ability to bind some bacteria strains. In this study, we report that Clu also binds specifically to late apoptotic cells but not to live, early apoptotic, or necrotic cells. Histones, which accumulate on blebs during the apoptotic process, represent privileged Clu-binding motifs at the surface of late apoptotic cells. As a consequence, Clu potentiates, both in vitro and in vivo, the phagocytosis of late apoptotic cells by macrophages. Moreover, the increased phagocytosis of late apoptotic cells induced by Clu favors the presentation and cross-presentation of apoptotic cell-associated antigens. Finally, we observed that, in a model of apoptotic cell-induced autoimmunity, and relative to control mice, Clu(-/-) mice develop symptoms of autoimmunity, including the generation of anti-dsDNA antibodies, deposition of immunoglobulins and complement components within kidneys, and splenomegaly. These results identify Clu as a new molecule partner involved in apoptotic cell efferocytosis and suggest a protective role for Clu in inflammation and autoimmune diseases.
Subject(s)
Antigen Presentation/genetics , Autoantigens/immunology , Autoimmune Diseases/immunology , Clusterin/immunology , Splenomegaly/immunology , Animals , Antibodies, Antinuclear/biosynthesis , Apoptosis/immunology , Autoantigens/genetics , Autoimmune Diseases/genetics , Autoimmune Diseases/pathology , Clusterin/genetics , Coculture Techniques , Cross-Priming/genetics , Dendritic Cells/cytology , Dendritic Cells/immunology , Gene Expression , Humans , Kidney/immunology , Kidney/pathology , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/immunology , Macrophages/cytology , Macrophages/immunology , Mice , Mice, Inbred C57BL , Mice, Knockout , Phagocytosis , Primary Cell Culture , Spleen/immunology , Spleen/pathology , Splenomegaly/genetics , Splenomegaly/pathologyABSTRACT
Neutrophils are short-lived innate immune cells that rapidly die by apoptosis. A rapid and efficient clearance of apoptotic cells is crucial to avoid autoimmunity. This process involves cell alterations, endocytic receptors expressed by phagocytic cells and soluble bridging molecules (opsonins) that facilitate internalization of apoptotic cells by phagocytes. Neutrophils constitutively express the prototypic long pentraxin PTX3 that binds to apoptotic cells and modulates their clearance. We thus evaluated whether endogenous PTX3 may interfere with the capture of apoptotic neutrophils. We observed that PTX3 accumulates in blebs at the surface of late apoptotic neutrophils, resulting from its active translocation from granules to the membrane. A neutralizing anti-PTX3 monoclonal Ab (mAb) inhibits the capture of late apoptotic neutrophils by macrophages. This study shows that intracellular PTX3 translocates at the surface of late apoptotic neutrophils and acts as an 'eat-me' molecule for their recognition and capture by macrophages.
Subject(s)
Apoptosis/physiology , C-Reactive Protein/metabolism , Macrophages/physiology , Neutrophils/metabolism , Phagocytosis/physiology , Serum Amyloid P-Component/metabolism , C-Reactive Protein/genetics , Cell Membrane/metabolism , Humans , Macrophages/cytology , Neutrophils/cytology , Protein Transport , Serum Amyloid P-Component/geneticsABSTRACT
Antineutrophil cytoplasmic antibodies (ANCA) are directed against enzymes found in the granules of the polymorphonuclear (PMN) leukocytes. They are detected by indirect immunofluorescence microscopy assays on human ethanol fixed neutrophils. Three different fluorescence patterns can be distinguished: a cytoplasmic pattern (cANCA), a perinuclear pattern (pANCA), and an atypical pattern (aANCA). The use of other fixatives, e.g., formalin and methanol, allows differentiation between the pANCA and the antinuclear antibodies. ANCA specificity is determined by solid phase assays (ELISA, immunodot, and multiplex assay). ANCA with high titres and defined specificities (antiproteinase 3 [PR 3] or antimyeloperoxidase [MPO]) are proven to be good serological markers of active primary systemic vasculitis: c/PR 3-ANCA for Wegener's granulomatosis and p/MPO-ANCA for microscopic polyangiitis. The former have higher sensitivity and specificity for Wegener's granulomatosis than the latter for microscopic polyangiitis. ANCA with low titres and unknown specificity have been detected in a wide range of inflammatory and infectious diseases leading to a critical reappraisal of the diagnostic significance of ANCA testing. Physicians must keep in mind the possible occurrence of infectious diseases like subacute endocarditis that could be dramatically worsened by irrelevant immunosuppressive therapy. ANCA findings in certain manifestations, such as the pulmonary-renal syndrome in which massive pulmonary hemorrhage can quickly be life-threatening, warrant ANCA testing as an emergency test for patient care.
Subject(s)
Antibodies, Antineutrophil Cytoplasmic/analysis , Antimicrobial Cationic Peptides/immunology , Blood Proteins/immunology , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique, Indirect , Humans , Immunoblotting , Myeloblastin/immunology , Neutrophils/immunology , Peroxidase/immunologyABSTRACT
Heat-shock proteins (HSPs) induce protective cytotoxic immune responses against tumour antigens. This property is related to their ability to bind to and to be internalized by DC (dendritic cells) before gaining access to the MHC class I processing pathway, a process called antigen cross-presentation. This process requires internalization of the antigen by DC via endocytic receptors. Owing to their particular immune properties, several studies were focused on the identification of HSP-binding elements on DC. We and others have reported that scavenger receptors are the main HSP-binding structures on human DC and have identified LOX-1 as one of these molecules. The binding of human Hsp70 to DC and the in vitro Hsp70-mediated antigen cross-presentation are inhibited by an anti-LOX-1 monoclonal antibody. In vivo, targeting LOX-1 with a tumour antigen using an anti-LOX-1 monoclonal antibody induces antitumour immunity. Thus scavenger receptors are certainly new promising targets for cancer immunotherapy.
Subject(s)
Antigens/immunology , Cross Reactions , Heat-Shock Proteins/physiology , Receptors, Immunologic/physiology , Adaptation, Physiological/immunology , Dendritic Cells/immunology , Dendritic Cells/metabolism , Heat-Shock Proteins/metabolism , Humans , Immunity, Innate , Receptors, Immunologic/metabolism , Receptors, Scavenger , Scavenger Receptors, Class EABSTRACT
The aim of this study was to evaluate the presence and the role of the serum soluble costimulatory molecule CD28 in patients with systemic lupus erythematosus (SLE), primary Sjögren's syndrome (SS), and systemic sclerosis (SSc). Soluble CD28 concentration was determined by ELISA in 45 patients with SLE, 45 patients with primary SS, 30 patients with SSc, and 45 healthy subjects. We also evaluated CD28 mRNA expression by semiquantitative RT-PCR, and the biological activity of recombinant soluble CD28 on T lymphocyte activity. Concentrations of soluble CD28 were significantly higher in patients with SLE, primary SS and SSc than in healthy subjects. Soluble CD28 concentrations were higher in patients with systemic primary SS than in patients with glandular-limited primary SS. PCR analysis suggested that soluble CD28 resulted from the shedding of the membrane form. In vitro assay revealed that soluble CD28 inhibits the anti-CD3 mAb induced T cell proliferation. Soluble CD28, which modulates the proliferation of T lymphocytes, could be associated with disease severity in patients with autoimmune disease, especially primary SS. These results suggest that soluble CD28 could play an important role in the regulation of autoimmune diseases.
Subject(s)
CD28 Antigens/blood , Lupus Erythematosus, Systemic/immunology , Scleroderma, Systemic/immunology , Sjogren's Syndrome/immunology , Adolescent , Adult , CD28 Antigens/genetics , Case-Control Studies , Cell Division/drug effects , Cells, Cultured , Female , Humans , Interleukin-2/metabolism , Linear Models , Male , Middle Aged , Muromonab-CD3/pharmacology , RNA, Messenger/analysis , Recombinant Proteins/pharmacology , Statistics, Nonparametric , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , T-Lymphocytes/metabolismABSTRACT
Allergic disorders are characterized by allergen-specific Th2-biased responses. Signals controlling Th2 cell polarization, especially those acting by polarizing dendritic cells (DC) into Th2-promoting DC (DC2), are not well known. Histamine, a mediator released by allergen-stimulated mast cells from allergic subjects, has been reported to activate human immature DC. We have therefore tested whether histamine affects DC polarization. We report here that histamine inhibits LPS-induced IL-12 production and polarizes uncommitted maturing DC into effector DC2. DC matured in the presence of histamine fail to produce IL-12 upon subsequent stimulation and prime Th2 responses, even in presence of IFN-gamma, a potent DC1-driving factor. All these effects are mediated through both H1 and H2 receptors. These data show that histamine is a potent DC2-polarizing factor and provide evidence for a novel mechanism that explains the initiation and maintenance of a predominant Th2 response in allergic disorders.
Subject(s)
Dendritic Cells/immunology , Histamine/pharmacology , Th2 Cells/immunology , Cell Differentiation , Cells, Cultured , Dendritic Cells/drug effects , Humans , Hypersensitivity/immunology , Interferon-gamma/biosynthesis , Interleukin-12/biosynthesis , Lipopolysaccharides/pharmacology , Myeloid Progenitor Cells/drug effects , Myeloid Progenitor Cells/immunologyABSTRACT
Adhesive interactions with stromal cells and the extracellular matrix are essential for the differentiation and migration of hematopoietic progenitors. In the erythrocytic lineage, a number of adhesion molecules are expressed in the developing erythrocytes and are thought to play a role in the homing and maturation of erythrocytic progenitors. However, many of these molecules are lost during the final developmental stages leading to mature erythrocytes. One of the adhesion molecules that remains expressed in mature, circulating erythrocytes is CD147. This study shows that blockade of this molecule on the cell surface by treatment with F(ab')(2) fragments of anti-CD147 monoclonal antibody disrupts the circulation of erythrocytes, leading to their selective trapping in the spleen. Consequently, mice develop an anemia, and de novo, erythropoietin-mediated erythropoiesis in the spleen. In contrast, these changes were not seen in mice similarly treated with another antierythrocyte monoclonal antibody with a different specificity. These results suggest that the CD147 expressed on erythrocytes likely plays a critical role in the recirculation of mature erythrocytes from the spleen into the general circulation. (Blood. 2001;97:3984-3988)
Subject(s)
Antigens, CD , Antigens, Neoplasm , Antigens, Surface , Avian Proteins , Blood Proteins , Cell Movement/drug effects , Erythrocytes/drug effects , Membrane Glycoproteins/pharmacology , Spleen/cytology , Animals , Antibodies, Monoclonal/pharmacology , Basigin , Erythrocytes/cytology , Erythropoiesis/drug effects , Hematocrit , Membrane Glycoproteins/immunology , Membrane Glycoproteins/physiology , Mice , Mice, Inbred Strains , Organ Size/drug effects , Phlebotomy , Time FactorsABSTRACT
To understand the lack of protective immunity observed after infection with parainfluenza virus type 3 (PIV3), we tested the effect of the virus on human monocytes and monocyte-derived immature dendritic cells (DCs). Expression of viral antigens on the cell surfaces correlated with replication of the virus, which was marginal in monocytes but extremely efficient in DCs. The virus increased monocyte survival at least in part through the production of granulocyte-macrophage colony-stimulating factor but, in contrast, accelerated DC apoptosis. In addition, PIV3 infection failed to activate monocytes but induced maturation of DCs with increased expression of CD54, HLA-DR, CD86, and CD83 and production of bioactive IL-12. However, PIV3-infected DCs demonstrated low stimulatory properties in DC-T cell cocultures, a finding that could not be attributed to the production of infectious virus or IL-10. These results demonstrate for the first time that PIV3 dramatically modifies the survival and/or the function of antigen-presenting cells and might therefore prevent the development of efficient antiviral immune responses.
Subject(s)
Dendritic Cells/virology , Leukocytes, Mononuclear/virology , Parainfluenza Virus 3, Human/physiology , Antigens, CD/analysis , Antigens, Viral/analysis , Apoptosis , B7-2 Antigen , Cell Differentiation , Cell Survival , Cells, Cultured , Dendritic Cells/immunology , Granulocyte-Macrophage Colony-Stimulating Factor/analysis , Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis , HLA-DR Antigens/analysis , Humans , Immunoglobulins/analysis , Intercellular Adhesion Molecule-1/analysis , Interleukin-12/analysis , Leukocytes, Mononuclear/immunology , Membrane Glycoproteins/analysis , RNA, Messenger/biosynthesis , Virus Replication , CD83 AntigenABSTRACT
Mast cells and immature dendritic cells (DC) are in close contact in peripheral tissues. Upon activation, mast cells release histamine, a mediator involved in the immediate hypersensitivity reaction. We therefore tested whether histamine could affect human DC activation and maturation. Histamine induces CD86 expression on immature DC in a dose-dependent (significant at 10(-7) M) and transient manner (maximal after 24-h stimulation). Histamine also transiently up-regulates the expression of the costimulatory and accessory molecules, CD40, CD49d, CD54, CD80, and MHC class II. As a consequence, immature DC exposed for 24 h to histamine stimulate memory T cells more efficiently than untreated DC. In addition, histamine induces a potent production of IL-6, IL-8, monocyte chemoattractant protein 1, and macrophage-inflammatory protein 1alpha by immature DC and also up-regulates IL-1beta, RANTES, and macrophage-inflammatory protein 1beta but not TNF-alpha and IL-12 mRNA expression. Histamine activates immature DC through both the H1 and H2 receptors. However, histamine-treated DC do not have a phenotype of fully mature cells, as they do neither show significant changes in the expression of the chemokine receptors, CCR5, CCR7 and CXC chemokine receptor 4, nor expression of CD83 de novo. These data demonstrate that histamine activates immature DC and induces chemokine production, thereby suggesting that histamine, via stimulation of resident DC, may participate locally in T cell stimulation and in the late inflammatory reaction associated with allergic disorders.
Subject(s)
Antigens, CD/biosynthesis , Chemokines/biosynthesis , Dendritic Cells/immunology , Dendritic Cells/metabolism , Histamine/pharmacology , Membrane Glycoproteins/biosynthesis , Adjuvants, Immunologic/pharmacology , Antigen Presentation/drug effects , B7-1 Antigen/biosynthesis , B7-2 Antigen , CD40 Antigens/biosynthesis , Cell Differentiation/immunology , Cells, Cultured , Coculture Techniques , Cytokines/biosynthesis , Dendritic Cells/pathology , Dose-Response Relationship, Immunologic , HLA-DR Antigens/biosynthesis , Histamine/metabolism , Histamine/physiology , Humans , Integrin alpha4 , Integrins/biosynthesis , Intercellular Adhesion Molecule-1/biosynthesis , Receptors, Histamine H1/physiology , Receptors, Histamine H2/physiology , Up-Regulation/immunologyABSTRACT
CD86 is a costimulatory molecule constitutively expressed by human antigen presenting cells which interacts with CD28 and CTLA-4 expressed by T cells. We have recently reported the identification of an alternatively spliced CD86 mRNA variant (CD86deltaTM) characterized by the deletion of exon 6 which encodes for the transmembrane domain. We report here the identification of an alternatively spliced variant (called CD86deltaEC) expressed by nonstimulated human monocytes and characterized by the deletion of exons 4 and 5 which encode for the extracellular V-like and C-like domains, respectively. The activation of monocytes by IFNgamma (i) induces the preferential expression of the transcript encoding for the membrane form and (ii) increases the expression of CD86 and of the accessory molecules CD40, CD49d and CD54. These results suggest that resting human monocytes may constitutively express different forms of CD86 which can then influence the activation of T cells.
Subject(s)
Alternative Splicing , Antigens, CD/genetics , Membrane Glycoproteins/genetics , RNA, Messenger/genetics , Amino Acid Sequence , B7-2 Antigen , Base Sequence , Cloning, Molecular , DNA, Complementary/chemistry , DNA, Complementary/genetics , Gene Expression Regulation , Humans , Molecular Sequence Data , Monocytes/cytology , Monocytes/metabolism , Sequence Analysis, DNAABSTRACT
CD86 is an important costimulatory molecule for the priming and activation of naive and memory T cells, respectively. Here, we show that soluble CD86 is detected in human serum. Soluble CD86 is produced by resting monocytes and results from an alternatively spliced transcript (CD86deltaTM) characterized by deletion of the transmembrane domain. Recombinant CD86deltaTM binds to CD28 and CTLA-4 and induces the activation of T cells after stimulation with anti-CD3 mAb. CD86deltaTM also induces IFNgamma production by virus-specific CD8+ memory human T cells stimulated with the Flu M1 peptide. The concentrations of soluble CD86 found in human serum are sufficient to induce biological activity. Soluble CD86 molecule, therefore, appears to be a functional costimulatory molecule playing a potentially important role in immune surveillance.
Subject(s)
Antigens, CD/physiology , Lymphocyte Activation/immunology , Membrane Glycoproteins/physiology , T-Lymphocytes/immunology , Amino Acid Sequence , Animals , Antigens, CD/biosynthesis , Antigens, CD/blood , Antigens, CD/genetics , B7-2 Antigen , COS Cells , Epitopes, T-Lymphocyte/immunology , Humans , Immunologic Memory/genetics , Interphase/immunology , Jurkat Cells , Lymphocyte Activation/genetics , Membrane Glycoproteins/biosynthesis , Membrane Glycoproteins/blood , Membrane Glycoproteins/genetics , Molecular Sequence Data , Monocytes/immunology , Monocytes/metabolism , RNA Splicing/immunology , RNA, Messenger/biosynthesis , RNA, Messenger/metabolism , Recombinant Proteins/biosynthesis , Solubility , Transcription, Genetic/immunology , Transfection/immunologyABSTRACT
Ciliary neurotrophic factor (CNTF) is a cytokine supporting the differentiation and survival of various cell types in the peripheral and central nervous systems. Its receptor complex consists of a non-signaling alpha chain, CNTFR, and two signaling beta chains, gp130 and the leukemia inhibitory factor receptor (LIFR). Striking phenotypic differences between CNTF- and CNTFR-deficient mice suggest that CNTFR serves as a receptor for a second, developmentally important ligand. We have identified this factor as a stable secreted complex of cardiotrophin-like cytokine (CLC) and the soluble receptor cytokine-like factor-1 (CLF). CLF expression was required for CLC secretion, and the complex acted only on cells expressing functional CNTF receptors. The CLF/CLC complex activated gp130, LIFR and signal transducer and activator of transcription 3 (STAT3) and supported motor neuron survival. Our results indicate that the CLF/CLC complex is a second ligand for CNTFR with potentially important implications in nervous system development.
Subject(s)
Cytokines/metabolism , Receptor, Ciliary Neurotrophic Factor/metabolism , Receptors, Cytokine/metabolism , Animals , COS Cells , Cell Differentiation/physiology , Cell Survival/physiology , Ligands , Motor Neurons/cytology , Motor Neurons/metabolism , Nerve Degeneration/physiopathology , Radioligand Assay , Tumor Cells, CulturedABSTRACT
Outer membrane protein (Omp)A is highly represented and conserved in the Enterobacteriaceae family. Using a recombinant OmpA from Klebsiella pneumoniae (P40), we have analyzed the interaction between OmpA and macrophages. We report that Alexa488-labeled P40 binds (at 4 degrees C) to murine and human macrophages in a dose-dependent manner and is rapidly internalized (at 37 degrees C). No binding or internalization of the Alexa488-labeled glycophorin A control protein is observed under the same conditions. Furthermore, P40 up-regulates the production of IL-1beta, IL-8, IL-10, IL-12, and TNF-alpha by human macrophages and of NO by the RAW 264.7 murine macrophage cell line. P40 also synergizes with IFN-gamma and suboptimal concentrations of LPS to up-regulate the production of these mediators. In conclusion, P40 binds to and activates macrophages. These data suggest that recognition of OmpA by macrophages may be an initiating event in the antibacterial host response.
Subject(s)
Bacterial Outer Membrane Proteins/immunology , Bacterial Outer Membrane Proteins/metabolism , Macrophage Activation/immunology , Macrophages/immunology , Macrophages/metabolism , Animals , Bacterial Outer Membrane Proteins/pharmacology , Cell Line , Cells, Cultured , Drug Synergism , Endocytosis/immunology , Flow Cytometry , Humans , Interferon-gamma/pharmacology , Lipopolysaccharides/pharmacology , Mice , Microscopy, Confocal , Molecular Weight , Protein Binding/immunologyABSTRACT
A cDNA encoding a novel human matrix metalloproteinase (MMP), named MMP-26, was cloned from fetal cDNA. The deduced 261-amino-acid sequence is homologous to macrophage metalloelastase (51.8% identity). It includes only the minimal characteristic features of the MMP family: a signal peptide, a prodomain and a catalytic domain. As with MMP-7, this new MMP does not comprise the hemopexin domain, which is believed to be involved in substrate recognition. A study of MMP-26 mRNA steady states levels reveals, among the tissue examined, a specific expression in placenta. MMP-26 mRNA could also be detected in several human cell lines such as HEK 293 kidney cells and HFB1 lymphoma cells. Recombinant MMP-26 was produced in mammalian cells and used to demonstrate a proteolytic activity of the enzyme on gelatin and beta-casein.
Subject(s)
Matrix Metalloproteinases/genetics , Placenta/enzymology , Pregnancy Proteins/genetics , Amino Acid Sequence , Animals , COS Cells , Catalytic Domain , Cell Line , Chlorocebus aethiops , DNA, Complementary/genetics , Expressed Sequence Tags , Gene Expression Profiling , Humans , Matrix Metalloproteinases/metabolism , Matrix Metalloproteinases, Secreted , Molecular Sequence Data , Organ Specificity , Protein Sorting Signals/genetics , Protein Structure, Tertiary , RNA, Messenger/metabolism , Recombinant Fusion Proteins/metabolism , Sequence Homology, Amino Acid , Substrate Specificity , TransfectionABSTRACT
We analyzed the interaction between a bacterial cell wall protein and dendritic cells (DCs). Outer membrane protein A from Klebsiella pneumoniae (kpOmpA) specifically bound to professional antigen presenting cells and was endocytosed by immature DCs via a receptor-dependent mechanism. kpOmpA signaled through Toll-like receptor 2, induced DCs to produce interleukin 12 and induced maturation of DCs. Whole antigen that was coupled to kpOmpA and injected into mice was taken up by DCs and delivered to the conventional cytosolic MHC class I presentation pathway. kpOmpA also primed antigen-specific CD8+ CTLs in the absence of CD4+ T cell help or adjuvant and elicited therapeutic immunity to antigen-expressing tumors. Thus, OmpA belongs to a class of proteins that are able to elicit CTL responses to exogenous antigen.
Subject(s)
Antigen Presentation , Bacterial Outer Membrane Proteins/immunology , Bacterial Outer Membrane Proteins/metabolism , Dendritic Cells/cytology , Dendritic Cells/immunology , Drosophila Proteins , Animals , Antigen-Presenting Cells/cytology , Antigen-Presenting Cells/immunology , Cell Differentiation , Cell Line , Endocytosis , Female , Histocompatibility Antigens Class I/metabolism , Humans , Klebsiella pneumoniae/immunology , Membrane Glycoproteins/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Neoplasms, Experimental/immunology , Neoplasms, Experimental/therapy , Ovalbumin/immunology , Receptors, Cell Surface/metabolism , Signal Transduction , T-Lymphocytes, Cytotoxic/immunology , Toll-Like Receptor 2 , Toll-Like ReceptorsABSTRACT
We have evaluated the expression and the involvement of membrane-associated TNF-alpha (mTNF-alpha) in human NK cell-mediated cytotoxicity. Results from FCM analysis show that peripheral blood NK cells constitutively express mTNF-alpha. In contrast, mTNF-alpha expression is undetectable on resting T cells, B cells and monocytes. Western blotting analysis confirmed that freshly purified NK cells express the 17-kDa soluble form (sTNF-alpha) and the 26-kDa transmembrane form of TNF-alpha. Stimulation with IL-2, IL-15 and IL-18 up-regulates TNF-alpha mRNA, sTNF-alpha and mTNF-alpha expression in NK cells. The role of mTNF-alpha in the cytotoxic activity of resting NK cells has been evaluated in in vitro cytotoxic assays using freshly purified NK cells fixed with paraformaldehyde as effector cells (in order to avoid the participation of cytotoxic soluble mediators such as perforin, granzymes or sTNF-alpha) and the TNF-alpha-sensitive Fas ligand- and TRAIL-resistant cell line KYM-1-D4 as target cell. Results show that fixed NK cells kill the KYM-1-D4 cells and that neutralizing anti-TNF-alpha antibodies partly prevent this effect. In contrast to the other types of peripheral blood mononuclear cells NK cells from adult blood constitutively express functional mTNF-alpha in the absence of prior contact with target cells or activation. These data demonstrate a novel mechanism of cell-mediated cytotoxicity by non-acitvated human peripheral blood NK cells.
Subject(s)
Killer Cells, Natural/immunology , Tumor Necrosis Factor-alpha/immunology , Cells, Cultured , Cytotoxicity, Immunologic/immunology , Gene Expression Regulation , Humans , Interleukin-15/immunology , Interleukin-15/pharmacology , Interleukin-18/immunology , Interleukin-18/pharmacology , Interleukin-2/immunology , Interleukin-2/pharmacology , Killer Cells, Natural/drug effects , Membrane Proteins/genetics , Membrane Proteins/immunology , Tumor Necrosis Factor-alpha/biosynthesis , Tumor Necrosis Factor-alpha/genetics , Up-RegulationABSTRACT
CTLA-4, expressed by activated T cells, transduces an inhibitory signal. We show here that PCR amplification of the coding sequence of CTLA-4 in nonstimulated human T lymphocytes results in the amplification of two transcripts of 650 and 550 bp. Sequencing shows that the larger form codes for membrane CTLA-4 and the 550-bp transcript is a spliced variant in which exon 2 coding for the transmembrane region is deleted. This spliced cDNA has been named CTLA-4delTM. The splicing induces a frame shift which results in the addition of 22 extra amino acids before a translational termination. Activation of T cells with phorbol 12-myristate 13-acetate plus ionomycin or anti-CD3 plus anti-CD28 monoclonal antibodies induces a suppression of CTLA-4delTM mRNA expression associated with a preferential expression of the membrane CTLA-4 mRNA, showing that CTLA-4delTM mRNA expression is restricted to nonactivated T cells. A soluble immunoreactive form of CTLA-4 was detected in the serum of 14 / 64 healthy subjects. These results suggest that nonstimulated T cells may constitutively produce a soluble form of CTLA-4 which may have an important role in the regulation of immune homeostasis.
Subject(s)
Alternative Splicing , Antigens, Differentiation/biosynthesis , Immunoconjugates , T-Lymphocytes/metabolism , Abatacept , Amino Acid Sequence , Animals , Antigens, CD , Antigens, Differentiation/genetics , Base Sequence , COS Cells , CTLA-4 Antigen , Cells, Cultured , Gene Expression , Humans , Lymphocyte Activation , Molecular Sequence Data , RNA, Messenger , Recombinant Fusion Proteins/genetics , Solubility , T-Lymphocytes/immunologyABSTRACT
Using the sequence of cosmids derived from chromosome 19p12, we have identified a gene encoding a novel protein, BSMAP (brain-specific membrane-anchored protein) and cloned cDNA encoding the full-length open reading frame. Northern blot analysis revealed that BSMAP mRNA is preferentially expressed at a high level in the brain. BSMAP has a putative transmembrane domain and is predicted to be a type-I membrane glycoprotein. Genomic sequence analysis revealed that the gene encoding BSMAP consists of eight exons spanning approximately 8 kb and lies 6 kb away from the gene encoding CLF-1 in a reverse orientation. Although no candidate genetic disorders were found to map either to this precise region of chromosome 19 or to the syntenic region of the mouse genome, the highly specific expression of BSMAP mRNA suggests a role for the protein in CNS function.